Efficacy and Safety Study of F373280

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 135 participants.

Also called NCT01831856

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 135 participants (enrolled count) (from the registry)
Sponsor
Pierre Fabre Medicament (from the registry)
Registry
  • NCT NCT01831856
  • EudraCT 2012-003487-48
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Czechia, Hungary, Italy, Poland, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01831856. Randomized; quadruple masking; primary purpose treatment. Start 2013-04 (actual); primary completion 2017-04-03 (actual). Results posted on 2019-07-02.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety Study of F373280
Intervention (Drug)
1g of F373280
Intervention (Drug)
Placebo
Lead sponsor
Pierre Fabre Medicament (class: industry)

Record details

Record id
cardio:ct-nct01831856
Content hash
5db23fe6829d78306cfb84c60abfc080371d92b9b6a1129aa46b004cf30be168